FRIDAY, Dec. 27, 2024 (HealthDay News) -- People with multiple sclerosis (MS) have been concerned that a COVID-19 infection could cause the symptoms of their nerve disease to become even worse.
The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...